A retrospective, multicenter and post-marketing study of safety and effectiveness of ustekinumab in Japanese patients with Crohn's disease
Latest Information Update: 05 Jul 2021
Price :
$35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2021 New trial record
- 27 Jun 2021 Interim results of 8-weeks published in the Journal of Gastroenterology and Hepatology.